X4 Pharmaceuticals Inc
$ 3.80
16.92%
04 Dec - close price
- Market Cap 284,169,000 USD
- Current Price $ 3.80
- High / Low $ 3.81 / 3.25
- Stock P/E N/A
- Book Value 2.45
- EPS -8.92
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.34 %
- ROE -1.57 %
- 52 Week High 26.82
- 52 Week Low 1.35
About
X4 Pharmaceuticals Inc. is a Boston-based clinical-stage biopharmaceutical company dedicated to developing innovative therapies for rare and serious diseases, particularly in back disorders. Leveraging its proprietary technology, the company is advancing a robust pipeline of investigational therapies designed to address significant unmet medical needs and improve patient outcomes. As X4 progresses through various clinical development phases, it embodies a strong potential for growth and impact within the biopharmaceutical sector, positioning itself as a key player in the evolving landscape of therapeutic solutions.
Analyst Target Price
$7.38
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-08 | 2025-05-05 | 2025-03-19 | 2024-11-13 | 2024-08-08 | 2024-05-07 | 2024-03-21 | 2023-11-09 | 2023-08-10 | 2023-05-04 | 2023-03-21 |
| Reported EPS | -0.69 | -3.47 | 0.04 | -0.2 | -0.18 | -0.07 | -0.26 | -0.1 | -0.01 | -0.33 | -0.16 | -0.29 |
| Estimated EPS | -0.8433 | -0.0883 | -3.75 | -0.1575 | -0.17 | 0.01 | -0.16 | -0.15 | -0.15 | -0.16 | -0.22 | -0.24 |
| Surprise | 0.1533 | -3.3817 | 3.79 | -0.0425 | -0.01 | -0.08 | -0.1 | 0.05 | 0.14 | -0.17 | 0.06 | -0.05 |
| Surprise Percentage | 18.1786% | -3829.7848% | 101.0667% | -26.9841% | -5.8824% | -800% | -62.5% | 33.3333% | 93.3333% | -106.25% | 27.2727% | -20.8333% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: XFOR
2025-10-24 04:02:09
This article appears to be a stub or an error page, as the only content present is "403 Forbidden" from Microsoft-Azure-Application-Gateway/v2. There is no substantive information about X4 Pharmaceuticals Inc. (48Q0) stock or the impact of dovish Fed policy.
2025-10-24 04:02:09
X4 Pharmaceuticals (NASDAQ: XFOR) announced an underwritten public offering of common stock and pre-funded warrants, with an option for underwriters to purchase an additional 15% of offered securities within 30 days. The proceeds are intended to fund the pivotal Phase 3 development of mavorixafor for chronic neutropenic disorders, along with general administrative expenses and working capital. The offering's completion is subject to market conditions, and Leerink Partners, Stifel, and Guggenheim Securities are serving as joint bookrunning managers.
2025-10-24 04:02:09
X4 Pharmaceuticals has announced a proposed underwritten public offering of its common stock and pre-funded warrants. The company intends to use the net proceeds to fund the pivotal Phase 3 development of mavorixafor for certain chronic neutropenic disorders, as well as for general corporate purposes. Leerink Partners, Stifel, and Guggenheim Securities are acting as joint bookrunning managers for the offering.
2025-10-24 04:02:09
X4 Pharmaceuticals (NASDAQ:XFOR) has announced a public offering of common stock and pre-funded warrants to raise capital for the Phase 3 development of mavorixafor, a drug for chronic neutropenic disorders. The company, with a market capitalization of $69.37 million and a current ratio of 3.19, recently began marketing mavorixafor under the brand name XOLREMDI in the U.S. This funding initiative comes after a recent strategic restructuring, including a 50% workforce reduction for $13 million in annualized cost savings, leadership changes, and a lowered price target from analysts Stifel and H.C. Wainwright.
2025-10-24 04:02:09
X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #1 (Strong Buy) due to an upward trend in its earnings estimates. This upgrade signifies a positive earnings outlook for the company, which is a strong indicator for stock price movement. The Zacks ranking system emphasizes the predictive power of changing earnings estimates for near-term stock performance.
2025-10-24 04:02:09
This article displays a "403 Forbidden" error, indicating that access to the requested content is denied. Therefore, no information regarding X4 Pharmaceuticals Inc. or commodity prices is available.
